Compare IQIYI Inc - ADR (IQ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Mesoblast Limited — how do they compare? IQIYI Inc - ADR trades at $1.34 (market cap $1.30B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.
| IQ | MESO | |
|---|---|---|
Market Cap | $1.30B | $2.21B |
Sector | Media | Technology |
52-Week High | $2.79 | $20.96 |
52-Week Low | $0.96 | $12.88 |
Enterprise Value | $2.88B | $2.21B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
